Literature DB >> 15949945

A new agent for treatment of acute respiratory distress syndrome: thymoquinone. An experimental study in a rat model.

Ahmet Feridun Isik1, Ismail Kati, Irfan Bayram, Hanefi Ozbek.   

Abstract

OBJECTIVE: Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) are important clinical problems in thoracic surgery and critical care medicine. Most of the treatment methods are still supportive. Thymoquinone has anti-inflammatory, spasmolytic, bronchodilator and antibacterial effects. We studied its effects on ALI/ARDS in a rat model.
METHODS: ALI/ARDS was developed in 40 Sprague-Dawley male rats (200-250 g in weight) by intratracheal instillation of human gastric juice (pH 1.2). Rats were treated with mechanic ventilator for 3h. There were five groups: Control group (n=11); Steroid group (n=10); Ethanol group (n=5); Thymoquinone group (n=9) and Thymoquinone+Steroid group (n=5). No instillation except gastric juice was applied in the first group. Thymoquinone was given in dosage of 6 mg/kg, metilprednisolone in dosage of 10mg/kg, ethanol 0.75 ml/kg intraperitoneally (IP). Blood gas analysis and compliance measurement were done. At the end of the third hour, rats were sacrificed and their lungs were excised for histopathological examination.
RESULTS: In the thymoquinone group, the ratio of arterial oxygen to the fraction of inspired oxygen (PO2/FiO2) was significantly better compared to the other groups (P=0.000-0.043). Static compliance measurements revealed higher values in thymoquinone and thymoquinone+steroid groups. Histopathological examinations showed that affected lung tissue is lower in groups 2 and 4 (P=0.000-0.027).
CONCLUSIONS: This study revealed that thymoquinone improved oxygenation while both thymoquinone and steroids protect lung tissue from hazardous effects of human gastric juice (pH 1.2) histopathologically.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15949945     DOI: 10.1016/j.ejcts.2005.04.012

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

Review 1.  Thymoquinone: A Promising Natural Compound with Potential Benefits for COVID-19 Prevention and Cure.

Authors:  Osama A Badary; Marwa S Hamza; Rajiv Tikamdas
Journal:  Drug Des Devel Ther       Date:  2021-05-03       Impact factor: 4.162

2.  Efficacy of thymoquinone in the treatment of experimental lipopolysaccharide-induced acute lung injury.

Authors:  Mustafa Çolak; Serdar Kalemci; Aylin Özgen Alpaydın; Volkan Karaçam; Ibrahim Meteoğlu; Osman Yılmaz; Bahriye Oya Itil
Journal:  Kardiochir Torakochirurgia Pol       Date:  2020-07-20

3.  Evaluation of the inflammatory response in a two-hit acute lung injury model using [18F]FDG microPET.

Authors:  Guang-Ju Zhou; Shou-Yin Jiang; Mao Zhang; Jian-Xin Gan; Guan-Yu Jiang
Journal:  Exp Ther Med       Date:  2013-08-13       Impact factor: 2.447

Review 4.  Therapeutic Potential and Pharmaceutical Development of Thymoquinone: A Multitargeted Molecule of Natural Origin.

Authors:  Sameer N Goyal; Chaitali P Prajapati; Prashant R Gore; Chandragouda R Patil; Umesh B Mahajan; Charu Sharma; Sandhya P Talla; Shreesh K Ojha
Journal:  Front Pharmacol       Date:  2017-09-21       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.